Comparison of some 3-(substituted-benzylidene)-1, 3-dihydro-indolin derivatives as ligands of tyrosine kinase based on binding mode studies and biological assay

Archives of Pharmacal Research

Volumn 29, Issue 11, 2006, Pages 1006-1017

  Ölgen, Süreyya ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Dock 4.0; N Substituted indole derivatives; p60c Src; Protein tyrosine kinase

Indexed keywords

EID: 33845364865     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02969285     Document Type: Article

References (36)

1. Akaho, E., Fujikawa, C., Runion, H. I., Hill, C. R., and Nakaho, H., A study on docking mode of hiv protease and their inhibitors. J. Chem. Software, 5, 147 -162 (1999).
2. Braud, E. M., Nourrisson, M. R., Tonnerre, A., Picot, C., LeBaut, G., Renard, P., Pfeiffer, B., and Tucker, G., Potential Inhibitors of angiogenesis. Part I: 3-(imidazolyl-4 (5)-ylmethylene) indolin-2-ones. J. Enzyme Inhib. Med. Chem., 18, 243-252 (2003).
3. Coda, A. C., Invernizzi, A. G., Righetti, P. P., and Tacconi, G., (Z)-and (E)-Arylindene-1,3-dihydro indol-2-ones: configuration, conformation, and infrared carbonyl stretching frequencies. J. Chem. Soc. Perkin Trans, 2, 615-619 (1984).
4. Cortes-Funes, H., Antiangiogenic agents. Drugs of Today, 38, 11-19 (2002).
5. Ewing T. J. A. and Kuntz, I. D., Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem., 18, 1175-1189 (1997).
6. Ewing T. J. A., Makino, S., Skillman, A. G., and Kuntz, I. D., Dock 4.0: Search strategies for automated molecular docking flexible molecule databases. J. Comp.-Aid. Mol. Des., 15, 411-428 (2001).
7. Fabbro, D., Parkinson, D., and Matter, A., Protein tyrosine kinase inhibitors: new treatment modalities. Curr. Opin. Pharmacol. 2, 374-381 (2002).
8. Folkman, J., Anti-angiogenesis: new concepts for theraphy of solid tumors. Ann. Surg., 175, 409-416 (1972).
9. Folkman, J., Tumor angiogenesis. Adv. Cancer Res., 43, 175-203 (1985).
10. Fong, T. A. T., Shawver, L. K., App, H., Sun, L., Tang, C., Rice, A., Kim, Y. H., Schreck, R., Chen, J., Dowd, B., Suto, E., Vasile, S., Wang, X., Hirth, K. P., and McMahon, G., SU 5416: a potent and selective Flk-1/KDR kinase inhibitor that blocks Flk-1 phosphorylation, endotelhial cell mitogenesis, and tumor growth. Proc. Am. Assoc. Cancer Res., 39, 560-567 (1998).
11. Fong, T. A. T., Shawer, L. K., Sun, L., Tang, C., App, H., Powell, T. J., Kim, Y. H., Schreck, R., Wang, X., Risau, W., Ullrich, A., Hirth, K. P., and McMahon, G., SU 5416: is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth for multiple tumor types. J. Cancer Res., 59, 99-106 (1999).
12. Hamby, J. M. and Showalter, H. D. H., Small molecule inhibitors of tumor promoted angiogenesis, including protein kinase inhibitors. Pharmacol. Ther., 82, 169-193 (1999).
13. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A., Discovery of a novel, potent and src family selective tyrosine kinase inhibitor. J. Biol. Chem., 271, 695-701 (1996).
14. Khols, D. W. D., Fry, D. W., and Kraker, A. J., Inhibitors of tyrosine kinase. Curr. Opin. Oncol., 9, 562-568 (1997).
15. Kuntz, I. D., Dock. 4.0 (University of California, San Francisco Web Site) (1998).
16. Levitzki, A. and Grazit, A., Tyrosine kinase inhibition: an approach to drug development. Science, 267, 1782-1788 (1995).
17. Lyne, P. D., Structure-based virtual screening: an overview. Drug Discovery Today, 7, 1047-1055 (2002).
18. Meng, E. C., Scoichet, B. K., and Kuntz, I. D., Automated docking with grid-base evaluation. J. Comput. Chem., 13, 505-524 (1992).
19. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., and Schlessinger, J., Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955-960 (1997).
20. Noonberg, S. B. and Benz, C. C., Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs, 59, 753-767 (2000).
21. c-Src receptor tyrosine kinase with the application of receptor docking studies. Farmaco, 60, 497-506 (2005).
22. c-Src receptor tyrosine kinase and investigation of the inhibition using receptor docking studies. J. Enzy. Inhib. Med. Chem. 18, 485-490 (2003).
23. Rewcastle, G. W., Palmer, B. D., Dobrusin, E. M., Fry, D. W., Kraker, A. J., and Denny, W. A., Tyrosine kinase inhibitors. 3. Structure-activity relationships for inhibition of protein tyrosine kinases by nuclear-substituted derivatives of 2, 2′-dithiobis (1-methyl-N-phenyl-1H-indole-3-carboxamide) . J. Med. Chem., 37, 2033-2042 (1994).
24. Roussidis, A. E. and Karamanos, N. K., Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment. In vivo, 16, 459-470 (2002).
25. Schulz-Gasch, T. and Stahl, M., Binding site characteristics in structure-based virtual screening: evaluation of current docking tools. J. Mol. Model., 9, 47-57 (2003).
26. Sun, L., Tran, N., Tang, F., App, H., Hirth, P., McMahon, G., and Tang, C., Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular tyrosine kinases. J. Med. Chem., 41, 2588-2603 (1998).
27. Sun, Y, Ewing T. J. A., Skillman, A. G., and Kuntz, I. D., CombiDOCK: Structure-based combinatorial docking and library design. J. Comp.-Aid. Mol. Des., 12, 597-604 (1998).
28. Sun, L., Tran, N., Liang, C., Tang, F., Rice, A., Schreck, R., Waltz, K., Shaever, L. K., McMahon, G., and Tang, C., Design, synthesis and evaluations of substituted 3-[(3- or 4-carboxy ethyl pyrrol-2-yl)methylindenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J. Med. Chem., 42, 5120-5130 (1999).
29. Sun, L., Tran, N., Liang, C., Hubbard, S., Tang, F., Lipson, K., Schreck, R., Zhou, Y., McMahon, G., and Tang, C., Identification of substituted 3-[(4, 5, 6, 7-Tetrahydro-1H-indole-2-yl) methylene]-1, 3-hydroindole-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rb tyrosine kinases. J. Med. Chem., 43, 2655-2663 (2000).
30. Taylor, V. C., Buckley, C. D., Douglas, M., Cody, A. J., Simmons, D. L., and Freeman, S. D., The myeloid-specific sialic acid binding receptor, CD33, associated with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem., 274, 11505-11512 (1999).
31. Taylor, R. D., Jewsbury, P. J., and Essex, J. W., A review of protein-small molecule docking methods. J. Comp.-Aid. Mol. Des., 16, 151-166 (2002).
32. Terrence, R. B., Protein-tyrosine kinase inhibitors. Drugs of the Future, 17, 119-131 (1992).
33. c-Src. J. Med. Chem., 43, 3134-3147 (2000).
34. Traxler, P. and Lyndon, N., Recent advances in protein tyrosine kinase inhibitors. Drugs of the Future, 20, 1261-1274 (1995).
35. Widler, L., Green, J., Missbach, M., Susa, M., and Altmann, E., 7-Alkyl- and 7-cycloalkyl-5-aryl-pyrrolo[2, 3-d]pyrimidines-potent inhibitors of the tyrosine kinase c-Src. Bioorg. Med. Chem. Lett., 11, 849-852 (2001).
36. Zhu, X., Kim, J. L., Newcomb, J. R., Rose, P. E., Stover, D. R., Toledo, L. M., Zhao, H., and Morgenstern, K. A., Structural Analysis of the Lymphocyte-Specific Kinase Lck in Complex with Non-Selective and Src Family Selective Kinase. Structure, 7, 651-661 (1999).